Why Guardant Health Jumped Nearly 5% on Tuesday
Guardant Health (NASDAQ: GH) shares were up 4.6% at Tuesday's close after the company announced its Guardant360 TissueNext test will be included among the diagnostic tests that at least one Medicare insurance service provider covers.
It's complicated; here's the simple and short explanation. The more specific a cancer diagnosis is, the more effective a response can be. The Guardant360 TissueNext test offers patients with advanced cancers a better diagnosis of their condition. Ergo, using the test's genomic sequencing capabilities, Guardant Health empowers oncologists to design a highly detailed plan of treatment.
Image source: Getty Images.
Source Fool.com
